Key Drivers
- Strong margins
- Solid liquidity
- Leverage risk
AIAI Summary
ANIP's strategic pivot makes it a high-conviction, cash‑funded rare‑disease commercial bet centered on Purified Cortrophin Gel, meaning near‑term upside is tightly coupled to sustaining Cortrophin revenue and successful rapid commercialization rather than steady generics cash flow. Key actionable watchpoints: confirm audited Cortrophin sales trends and Medicare/payer access stability over the next few quarters (reverification and co‑pay funding) before adding risk exposure, because reimbursement setbacks or mis‑timed SG&A scaling would materially compress margins and force dilutive financing or impairments.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Solid liquidity
- •Leverage risk
ANIP delivers strong margins and free cash flow with solid liquidity, but meaningful leverage, large intangibles and high SG&A (no dividend) heighten downside risk.
Price Behavior
Key Price Behavior Insights:
- •Modest downtrend
- •Clear nearby support
- •Resistance band established
ANIP has shown a modest downtrend over the last month (≈4% drop from $77.77 to $74.67) with lower highs and a local low at $70.49, making $76–$78 short-term resistance and $70.49 clear support—break below that support would likely trigger deeper selling while a reclaim above $76–$78 would reopen upside toward prior highs.
~4% decline from $77.77 to $74.67 over the last month with a local low of $70.49
Sentiment & News
Key News Insights:
- •Record results
- •Cortrophin momentum
- •Execution risk
ANI reported record FY/Q4 results, strong rare‑disease momentum (Cortrophin Gel), reaffirmed >$1B 2026 revenue guidance, and investor engagement amid analyst upside but noted execution/timing risks and insider share moves.
Positive top‑line and margin momentum supports upside, but near‑term stock performance hinges on Cortrophin sales cadence and execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings